Your session is about to expire
← Back to Search
Virus Therapy
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Phase 1 & 2
Waitlist Available
Led By Roger Cohen, MD
Research Sponsored by Codiak BioSciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called CDK-002 for patients with advanced cancers that haven't responded to other treatments. The drug is injected directly into the tumor to try to shrink it or stop its growth. Flavopiridol is the first CDK inhibitor to enter clinical trials.
Eligible Conditions
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To determine the safety and tolerability of ascending doses of CDK-002
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CDK-002Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CDK-002
2020
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Codiak BioSciencesLead Sponsor
2 Previous Clinical Trials
11 Total Patients Enrolled
Roger Cohen, MDPrincipal InvestigatorUniversity of Pennsylvania Hospital
4 Previous Clinical Trials
233 Total Patients Enrolled